Psoriatic Disease
New tool uses clinical variables to predict psoriatic arthritis in patients with psoriasis
A new tool using readily available clinical variables to predict psoriatic arthritis risk in patients with psoriasis demonstrated reasonable accuracy and good model performance, according to data published in Arthritis & Rheumatology.
Bimekizumab sustains effectiveness in psoriatic arthritis over 52 weeks
Bimekizumab remains effective after 52 weeks in patients with psoriatic arthritis, with no new safety concerns, according to data published in Annals of the Rheumatic Diseases.
FDA expands approval of abatacept for children with psoriatic arthritis
The FDA has approved a supplemental biologics licensing application from Bristol Myers Squibb expanding the indication of abatacept to include children aged 2 years and older with psoriatic arthritis, according to a company press release.
Newly diagnosed psoriatic disease associated with autoimmune disease risk
Newly diagnosed psoriatic disease may bring with it a significantly increased risk for autoimmune disease incidences, according to a study.
Taking ‘shots on goal’: The continuing fight to bring precision medicine to rheumatology
Patients across health care specialties have in recent years come to expect some form of individually tailored care — or precision medicine — as part of their disease management.
FDA denies Stelara biosimilar application from Alvotech
The FDA has denied a biologics license application from Alvotech for its biosimilar to ustekinumab, citing “certain deficiencies” at the company’s facility in Reykjavik, Iceland, according to the manufacturer.
FDA approves Abrilada as second interchangeable adalimumab biosimilar
The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.
Adalimumab biosimilar ‘costs more than double’ Humira’s launch price despite discount
Although the current net price of adalimumab biosimilar Amjevita is lower for commercial health plans than that of the originator, it is nonetheless “more than double” what Humira cost at launch in 2003, according to a research letter.
‘The elephant in the room’: Age, disease-related factors may drive JAK safety signals
SAN DIEGO — Patient age and disease-related factors may be driving safety signals in medications used to treat rheumatoid arthritis and psoriatic disease, according to a speaker at the 2023 Congress of Clinical Rheumatology West.
Psoriatic disease ‘decision tree’ needed to match treatment choices with target domains
SAN DIEGO — The varying domains of psoriatic disease create challenges in defining treatment algorithms, according to a speaker at the 2023 Congress of Clinical Rheumatology West.